MW005 shown to be safe and well-tolerated Data provides clinical efficacy proof-of-concept based on complete clearance of target lesions YAVNE,...
In MAESTRO-NASH, a 52-week serial liver biopsy Phase 3 study in more than 950 patients, resmetirom achieved both primary endpoints...
Findings Published in the Journal of Medicinal Chemistry Demonstrate Compound’s Exceptional Selectivity for mTORC1 over mTORC2 Tumor Regressions Observed During...
LIfT BioSciences investors increase investment in LIfT and Johnson and Johnson welcomes LIfT into JLABS Additional investment supports plans for...
More than 13,000 ChristianaCare employees will have access to Wellthy’s hands-on approach to help them balance work, life and careNEW...
MINNEAPOLIS, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the...
– US board-certified medical oncologist with extensive global clinical and regulatory experience advancing oncology medicines from early development stages through...
GFH009 is First CDK9 Inhibitor Monotherapy to Achieve Compete Response in Acute Myeloid Leukemia Anticancer Effects Observed Across Multiple Dose...
SAB brings extensive expertise in precision oncology, drug development, and early phase clinical trialsNEW HAVEN, Conn., Dec. 13, 2022 (GLOBE...
Marc Malandro POAI Scientific Advisory BoardEAGAN, Minn., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) today announced the...
Steven Tuch, Chief Financial Officer Steven Tuch, Chief Financial Officer Steven Tuch, Chief Financial Officer HIGH POINT, N.C., Dec. 13,...
Patients treated in dose-escalation portion of Phase 1/2 study evaluating seclidemstat in combination with azacitidine 50% overall response rate among...
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical...
JERUSALEM, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau," or the “Company”), the...
In December 2022, the 15th patient was dosed with IMX-110IMX-110 clinical trial data expected to be released on a rolling...
Significant single-agent activity in diffuse large B-cell lymphoma (DLBCL) cell models and in mouse model showed superiority to lenalidomide (Revlimid®)...
Additional analyses of non-small cell lung cancer (NSCLC) studies support the efficacy of plinabulin monotherapy in reducing the mean duration...
ERAS-3490, an orally available small molecule KRAS G12C inhibitor, has demonstrated robust nonclinical CNS and systemic activitySAN DIEGO, Dec. 13,...
Accomplished scientist with a diverse range of skills from general wet lab technique to company-wide operations managementOCALA, Fla., Dec. 12,...
--FemCerv®, the first endocervical tissue sampler of its kind in the detection of cervical cancer, was well-received after being presented...